Bone Disease Associated with Inactivating Aromatase Mutations and its Management.

Calcif Tissue Int

Department of Medicine, Surgery and Neurosciences, University of Siena, Policlinico Santa Maria Alle Scotte, Siena, Italy.

Published: January 2025

Aromatase deficiency (ORPHA:91; OMIM: 613,546) is a rare, autosomal recessive disorder due to loss of function mutations in the CYP19A1 gene, described in both genders with an estimated incidence below 1/1000000. While in female the clinical manifestations generally occur at birth or in early infancy, and mainly involve sexual characteristics, in men clinical signs of aromatase deficiency mostly occur in puberty and especially in late puberty, so that diagnosis is generally established after the second decade due to tall stature, unfused epiphyses and reduced bone mass. Here we review the available information concerning the skeletal and extraskeletal phenotype and the clinical management of bone health in patients with aromatase CYP19A1 gene mutations.

Download full-text PDF

Source
http://dx.doi.org/10.1007/s00223-024-01330-0DOI Listing

Publication Analysis

Top Keywords

aromatase deficiency
8
cyp19a1 gene
8
bone disease
4
disease associated
4
associated inactivating
4
aromatase
4
inactivating aromatase
4
aromatase mutations
4
mutations management
4
management aromatase
4

Similar Publications

Bone Disease Associated with Inactivating Aromatase Mutations and its Management.

Calcif Tissue Int

January 2025

Department of Medicine, Surgery and Neurosciences, University of Siena, Policlinico Santa Maria Alle Scotte, Siena, Italy.

Aromatase deficiency (ORPHA:91; OMIM: 613,546) is a rare, autosomal recessive disorder due to loss of function mutations in the CYP19A1 gene, described in both genders with an estimated incidence below 1/1000000. While in female the clinical manifestations generally occur at birth or in early infancy, and mainly involve sexual characteristics, in men clinical signs of aromatase deficiency mostly occur in puberty and especially in late puberty, so that diagnosis is generally established after the second decade due to tall stature, unfused epiphyses and reduced bone mass. Here we review the available information concerning the skeletal and extraskeletal phenotype and the clinical management of bone health in patients with aromatase CYP19A1 gene mutations.

View Article and Find Full Text PDF
Article Synopsis
  • Differences of sex development (DSD) encompasses a range of congenital conditions affecting chromosomal, gonadal, and anatomical sex development, often linked to atypical hormonal exposure or internal genital abnormalities.
  • DSD can manifest in various clinical phenotypes, leading to diagnoses at birth, during adolescence due to changes in virilization, or pubertal delays.
  • This review highlights rare causes of 46,XX DSD beyond congenital adrenal hyperplasia (CAH), focusing on their genetic, clinical characteristics, as well as puberty and fertility outcomes.
View Article and Find Full Text PDF

Diagnosis and management of non-CAH 46,XX disorders/differences in sex development.

Front Endocrinol (Lausanne)

May 2024

Department of Pediatric Endocrinology and Diabetes, School of Medicine, Marmara University, Istanbul, Türkiye.

Article Synopsis
  • Prenatal exposure to androgens can disrupt sexual development in individuals with a 46,XX chromosome pattern, commonly leading to disorders/differences in sex development (DSD).
  • The majority of these cases are due to congenital adrenal hyperplasia (CAH) resulting from 21-hydroxylase deficiency, but there are rare forms of CAH and other genetic factors that can also contribute to 46,XX DSD.
  • The management of 46,XX DSD is complex due to uncertainties regarding gonadal function and gender outcomes, making diagnosis and treatment challenging.
View Article and Find Full Text PDF

Estradiol is an important regulator of bone accumulation and maintenance. Circulating estrogens are primarily produced by the gonads. Aromatase, the enzyme responsible for the conversion of androgens to estrogen, is expressed by bone marrow cells (BMCs) of both hematopoietic and nonhematopoietic origin.

View Article and Find Full Text PDF

Background: Aromatase deficiency is a rare disorder, with only a few cases reported in India. We describe a single-center experience in western India, with a systematic review of genetically proven 46,XX aromatase deficiency patients to evaluate hormonal parameters.

Methods: Retrospective review of case records, collating phenotypic and genotypic data and molecular modeling.

View Article and Find Full Text PDF

Want AI Summaries of new PubMed Abstracts delivered to your In-box?

Enter search terms and have AI summaries delivered each week - change queries or unsubscribe any time!